Citations

Mayo Clinic

Clear

422 citation(s) found for "Yun, M R".

Dynamic monitoring of minimal residual disease in newly‐diagnosed multiple myeloma
Yang, Pei‐Yu , Xu, Weiling , Liang, Xinyue , Yu, Shanshan , Yi, Xingcheng , Liu, Mengmeng , Tian, Mengru, Yue, Tingting , Yan, Yurong, Hu, Zhongli, Zhang, Nan , Wang, Jingxuan , Hu, Rui , Kumar, Shaji , Jin, Fengyan , Kumar, Shaji K , Dai, Yun , Jin, Fengyan , Yue, Tingting, Zhang, Yingjie , Guo, Qiang , Sun, Xiaoxiao , Dai, Yun

American Journal of Hematology | December 21, 2022 | Volume: 98 | Issue: 3 | Pages: No page available

10.1002/ajh.26810 | PMID 36540935 Get It

Diagnostic Performance of ACR and Kwak TI-RADS for Benign and Malignant Thyroid Nodules: An Update Systematic Review and Meta-Analysis
Kang, Yun Jin , Stybayeya, Gulnaz , Lee, Ju Eun , Hwang, Se Hwan , Stybayeva, Gulnaz , Hwang, Se Hwan , Lee, Ju Eun

Cancers | December 2, 2022 | Volume: 14 | Issue: 23 | Pages: 5961

10.3390/cancers14235961 | PMID 36497443 Get It

(1) Background: To determine the optimal cut-off values of two risk stratification systems to discriminate malignant thyroid nodules and to compare the diagnostic performance; (2) Methods: True and false positive and negative data were collected, and methodological quality was assessed for forty-six studies involving 39,085 patients; (3) Results: The highest area under the receiver operating characteristic (ROC) curve (AUC) of ACR and Kwak TI-RADS were 0.875 and 0.884. Based on the optimal sensitivity and specificity, the highest accuracy values of ROC curves or diagnostic odds ratios (DOR) were taken as the cut-off values for TR4 (moderate suspicious) and 4B. The sensitivity, specificity, DOR, and AUC by ACR (TR4) and Kwak TI-RADS (4B) for malignancy risk stratification of thyroid nodules were 94.3% and 96.4%; 52.2% and 53.7%; 17.5185 and 31.8051; 0.786 and 0.884, respectively. There were no significant differences in diagnostic accuracy in any of the direction comparisons of the two systems; (4) Conclusions: ACR and Kwak TI-RADS had good diagnostic performances (AUCs > 85%). Although we determined the best cut-off values in individual risk stratification systems based on statistical assessment, clinicians can adjust the optimal cut-off value according to the clinical purpose of the ultrasonography because raising or lowering cut-points leads to reciprocal changes in sensitivity and specificity.
Identification of IL-4 As a Key Regulator of CAR T-Cell Exhaustion Using Functional Genomics and Correlates of the Zuma-1 Clinical Trial
Stewart, Carli M. , Ogbodo, Ekene J. , Manriquez-Roman, Claudia, Yun, Kun , Sirpilla, Olivia , Girsch, James H. , Huynh, Truc, Mattie, Mike , Filosto, Simone, Stewart, Carli , Cox, Michelle J. , Sakemura, Reona , Can, İsmail , Huynh, Truc , Siegler, Elizabeth L. , Kim, Jaeyeon , Scholler, Nathalie , Kenderian, Saad S.

Blood | November 29, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 4536-4537

10.1182/blood-2022-160219 Get It

Chimeric Antigen Receptor Engineering of Mesenchymal Stromal Cells (CAR-MSC) Enhance Immunosuppression and Outcomes in Graft Versus Host Disease (GvHD) Preclinical Models
Sirpilla, Olivia , Girsch, James H. , Huynh, Truc, Schick, Kendall J. , Manriquez-Roman, Claudia, Yun, Kun , Stewart, Carli M. , Ogbodo, Ekene J. , Sakemura, Reona , Hefazi, Mehrdad , Huynh, Truc , Cox, Michelle J. , Can, İsmail , Stewart, Carli , Siegler, Elizabeth L. , Kenderian, Saad S.

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 1579-1580

10.1182/blood-2022-158872 Get It

CD19 Antigen Occupancy on Cancer Cells with the CD19 Monoclonal Antibody Tafasitamab Improves the Activation, Antitumor Efficacy, and Safety Profile of CART19 Cell Therapy
Manriquez-Roman, Claudia, Horvei, Paulina , Huynh, Truc, Girsch, James H. , Sirpilla, Olivia , Yun, Kun , Stewart, Carli M. , Ogbodo, Ekene J. , Fonkoua, Lionel Aurelien Kankeu , Ruff, Michael W. , Ilieva-Babinsky, Kristina, Patra-Kneuer, Maria , Heitmüller, Christina, Ding, Wei , Nowakowski, Grzegorz S. , Sakemura, Reona , Cox, Michelle J. , Huynh, Truc , Stewart, Carli , Can, İsmail , Adada, Mohamad M , Hefazi, Mehrdad , Augsberger, Christian , Steidl, Stefan, Parikh, Sameer A. , Kay, Neil E. , Siegler, Elizabeth L. , Kenderian, Saad S.

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 2362-2364

10.1182/blood-2022-158273 Get It

Genomic and Transcriptional Profiling Stratifies Vq Myeloma Lines into Two Clusters with Distinct Risk Signatures and Drug Responses
Flietner, Evan, Yu, Mei , Zhou, Yun , Feng, Yubin, Wen, Zhi , Sun, Yuqian, Burns, Robert, Patnaik, Mrinal M. , Asimakopoulos, Fotis , Zhang, Jing , Rajagopalan, Adhithi , Veltri, Anthony J. , Lasho, Terra L. , Callander, Natalie S. , Wang, Demin

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 9935-9936

10.1182/blood-2022-162827 Get It

A Simple Risk-Scoring Model for Estimating the Prognostic Impact of 1q Gain in Patients with Newly-Diagnosed Multiple Myeloma
Jin, Fengyan, Yang, Pei‐Yu , Chen, Haimin , Liang, Xinyue , Xu, Weiling , Yu, Shanshan , Yi, Xingchen, Tian, Mengru, Yue, Tingting , Yan, Yurong, Hu, Zhongli, Kumar, Shaji , Zhou, Fan , Jin, Fengyan , Huang, Wenyang , Guo, Qiang , Yue, Tingting, Li, Mengyao , Zhang, Yingjie , Zhang, Mengxue , Dai, Yun

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 4360-4361

10.1182/blood-2022-168602 Get It

TET2 Down-Regulation Confers Bortezomib Resistance in Multiple Myeloma
Liu, Xiaobo , Yang, Ting , Kumar, Shaji , Jin, Fengyan, Dai, Yun , Jin, Fengyan

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 4185-4186

10.1182/blood-2022-168239 Get It